Myasthenia gravis: vizsgálatok itt: Németország
23 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 13.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
- Where
- Bochum, Essen, Goettingen, Jena, Leipzig, Rüdersdorf, Wuerzburg
- Életkor
- 18 év and over
- People
- 120 worldwide
- Run by
- UCB Biopharma SRL
See details and how to joinNCT07463521 · EU 2025-524756-54-00 - 3. fázisTaking peopleA Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
- Where
- Bochum, Essen, Goettingen, Jena, Leipzig, Rüdersdorf, Wuerzburg
- Életkor
- 18 év and over
- People
- 100 worldwide
- Run by
- UCB Biopharma SRL
See details and how to joinNCT07465289 · EU 2025-524757-14-00 - 3. fázisTaking peopleA Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
- Where
- Berlin, Goettingen, Ulm
- Életkor
- 18 év and over
- People
- 199 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT04951622 · EU 2023-504152-97-00 - No phaseTaking peopleHolistic Assessment and Remote Digital MONitoring of mYasthenia Gravis Via MyoSense 360
- Where
- Berlin, Bochum, München
- Életkor
- 18 év and over
- People
- 100 worldwide
- Run by
- Ad scientiam
See details and how to joinNCT07323316 - 2. fázisTaking peopleADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis
- Where
- Altenburg, Berlin, Goettingen, Wuerzburg
- Életkor
- 18 év and over
- People
- 40 worldwide
- Run by
- argenx
See details and how to joinNCT07673627 · EU 2025-522939-33-00 - 2/3. fázisCsak meghívásosEvaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis
- Where
- Berlin, Essen
- Életkor
- 2 év to 18 év
- People
- 12 worldwide
- Run by
- argenx
See details and how to joinNCT05374590 · EU 2023-507379-23-00 - 3. fázisTaking peopleComparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis
- Where
- Altenburg, Bochum, Erlangen, Freiburg im Breisgau, Muenster, Rüdersdorf
- Életkor
- 18 év to 74 év
- People
- 115 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07217587 · EU 2025-521130-28-00 - 3. fázisTaking peopleA Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)
- Where
- Freiburg im Breisgau
- Életkor
- 18 év to 80 év
- People
- 195 worldwide
- Run by
- Dianthus Therapeutics
See details and how to joinNCT07647510 · EU 2026-525298-38-00 - No phaseTaking peopleADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
- Where
- Berlin, Göttingen, Würzburg
- Életkor
- 18 év and over
- People
- 70 worldwide
- Run by
- argenx
See details and how to joinNCT07294170 - 3. fázisTaking peopleEfficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
- Where
- Berlin, Bochum, Dresden, Duesseldorf, Goettingen, Gummersbach, Hanover, Leipzig, Luebeck, Ulm
- Életkor
- 18 év and over
- People
- 264 worldwide
- Run by
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
See details and how to joinNCT06463587 · EU 2023-507746-83-00 - 2/3. fázisTaking peopleA Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis
- Where
- Essen
- Életkor
- 2 év to 17 év
- People
- 12 worldwide
- Run by
- argenx
See details and how to joinNCT06392386 · EU 2023-506159-12-00 - 2. fázisTaking peopleADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
- Where
- Altenburg, Berlin, Goettingen, Wuerzburg
- Életkor
- 18 év and over
- People
- 70 worldwide
- Run by
- argenx
See details and how to joinNCT07284420 · EU 2025-522492-28-00 - 1/2. fázisNot yet taking people in NémetországA double-blind, randomised, placebo-controlled, first-in-human (FIH) Phase I/IIa, multi-centre trial to assess safety, tolerability, and immune response of single and multiple ascending doses of TOL2 (Immune Tolerising Agent) in patients with generalised myasthenia gravis
- Where
- Hamburg, Muenster, Munich
- Életkor
- 18 év and over
- People
- 55 worldwide
- Run by
- Bonsai Biotherapeutics AB
See details and how to join2024-515627-10-00 - 3. fázisTaking peopleStudy to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
- Where
- Bochum, Essen, Goettingen, Magdeburg, Wuerzburg
- Életkor
- 18 év to 80 év
- People
- 231 worldwide
- Run by
- Immunovant Sciences GmbH
See details and how to joinNCT07039916 · EU 2024-515979-35-00 - 2/3. fázisTaking peopleKYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
- Where
- Berlin, Bochum, Hamburg, Hanover, Jena, Magdeburg, Munich
- Életkor
- 18 év to 75 év
- People
- 66 worldwide
- Run by
- Kyverna Therapeutics
See details and how to joinNCT06193889 · EU 2023-509892-17-00 - No phaseTaking peopleStudy of Ultomiris® (Ravulizumab) Safety in Pregnancy
- Where
- Essen
- People
- 75 worldwide
- Run by
- Alexion Pharmaceuticals, Inc.
See details and how to joinNCT06312644 - 4. fázisTaking peopleA Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab
- Where
- Bochum
- Életkor
- 18 év and over
- People
- 75 worldwide
- Run by
- Alexion Pharmaceuticals, Inc.
See details and how to joinNCT07221838 · EU 2025-522555-26-00 - No phaseTaking peopleRegistry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)
- Where
- Hanover
- Életkor
- 18 év and over
- People
- 500 worldwide
- Run by
- Alexion Pharmaceuticals, Inc.
See details and how to joinNCT04202341 - No phaseTaking peopleA Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa
- Where
- Altenburg, Bochum, Göppingen, Göttingen, Gummersbach, Jena, Würzburg
- Életkor
- 18 év and over
- People
- 680 worldwide
- Run by
- argenx
See details and how to joinNCT06298565 - No phaseTaking peopleA Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.
- Where
- Bochum
- People
- 279 worldwide
- Run by
- argenx
See details and how to joinNCT06299748 - 2/3. fázisTaking peopleA Long-Term Follow-Up Study for Participants Previously Treated With KYV-101
- Where
- Berlin, Bochum, Hamburg, Hanover
- Életkor
- 18 év and over
- People
- 70 worldwide
- Run by
- Kyverna Therapeutics
See details and how to joinNCT07403188 · EU 2024-511198-31-00 - No phaseCsak meghívásosDevelopment and Validation of the FBIndex to Determine the Risk of Falls for Patients With Neuromuscular Disorders
- Where
- München
- Életkor
- 18 év to 65 év
- People
- 108
- Run by
- LMU Klinikum
See details and how to joinNCT06605612 - No phaseCsak meghívásosThe Use of Assistive Gait Devices Can Reduce the Risk of Falls in Patients With Neuromuscular Diseases Following a Training Period.
- Where
- Bad Feilnbach
- Életkor
- 65 év to 65 év
- People
- 30
- Run by
- LMU Klinikum
See details and how to joinNCT07072676